• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Identification of biomarkers for precision medicine in patients with clear cell renal cell carcinoma

Research Project

Project/Area Number 20K16457
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 50020:Tumor diagnostics and therapeutics-related
Research InstitutionKansai Medical University

Principal Investigator

大杉 治之  関西医科大学, 医学部, 助教 (80826884)

Project Period (FY) 2020-04-01 – 2025-03-31
Project Status Granted (Fiscal Year 2023)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2023: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000)
Fiscal Year 2022: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2021: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Keywords腎細胞がん / PBRM1 / in situ hybridization / 淡明細胞型 / 腎細胞癌 / pT3a / 再発 / 腎部分切除術 / 淡明細胞型腎細胞がん / 再発予測 / 免疫組織化学検査 / 淡明細胞型腎細胞癌 / バイオマーカー / 個別化医療
Outline of Research at the Start

淡明細胞型腎細胞癌において、遺伝子変異が発症に関与することが明らかになっているが、各々の変異の臨床的意義は十分に理解されていない。また、転移・再発を来した腎細胞癌に対して薬物治療が行われるが、薬物の選択は臨床データから得られる予後予測分類に委ねられており、実臨床において予後や治療反応性を予測できるバイオマーカーは存在しない。PBRM1免疫染色結果が術後再発を予測する有用なバイオマーカーであることを見出しており、本研究では、NanoString社のnCounterを用いて遺伝子異常と免疫形質の相関、予後や治療効果を検証し、予後予測や治療選択の指標となるバイオマーカーを確立し、個別化医療を目指す。

Outline of Annual Research Achievements

淡明細胞型腎細胞がんの発生にPBRM1遺伝子がどの様に関わっているのか、またこのマーカーが再発予測や治療効果予測マーカーになり得るのかなどの検討を行った。
淡明細胞型腎細胞がんの組織切片においてPBRM1蛋白の発現低下の傾向や特徴に関しては、発表や報告を行ってきた(H.Ohsugi, Ann Surg Oncol; 28, 2359-2366, 2021.)。
PBRM1の蛋白発現と遺伝子発現に関しては、すでに相関 性があることが示されているが、がん細胞でのRNAレベルにおいてPBRM1の発現低下がどのような機序で起きているかは示されていない。これを明らかにするために、in situにての評価を本年度の目標とした。

Current Status of Research Progress
Current Status of Research Progress

2: Research has progressed on the whole more than it was originally planned.

Reason

PBRM1のViewRNAプローブの作成を徳島分子病理研究所に委託し行った。
現在も解析中であるが、実際のヒトの淡明細胞型腎細胞がんの組織検体では、RNAの評価がやや難渋している。
コントロールとの遺伝子発現の比較が、うまくできておらず、引き続きの追加解析が必要である。

Strategy for Future Research Activity

in situ hybridizationの条件を見直し、コントロールとの比較をどのように評価するか検討していく。
また、実臨床でも使用可能なことを目標としており、実臨床での検体数を増やして、更なる解析を試みる。

Report

(4 results)
  • 2023 Research-status Report
  • 2022 Research-status Report
  • 2021 Research-status Report
  • 2020 Research-status Report
  • Research Products

    (11 results)

All 2022 2021 2020

All Journal Article (7 results) (of which Int'l Joint Research: 3 results,  Peer Reviewed: 7 results,  Open Access: 5 results) Presentation (4 results) (of which Int'l Joint Research: 3 results)

  • [Journal Article] Histologic-based tumor-associated immune cells status in clear cell renal cell carcinoma correlates with gene signatures related to cancer immunity and clinical outcomes2022

    • Author(s)
      Ohe C, Yoshida T, Ikeda J, Tsuzuki T, Ohashi R, Ohsugi H, Atsumi N, Yamaka R, Saito R, Yasukochi Y, Higasa K, Kinoshita H and Tsuta K.
    • Journal Title

      Biomedicines

      Volume: 10 Issue: 2 Pages: 323-323

    • DOI

      10.3390/biomedicines10020323

    • Related Report
      2022 Research-status Report 2021 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] PBRM1 Immunohistochemical Expression Profile Correlates with Histomorphological Features and Endothelial Expression of Tumor Vasculature for Clear Cell Renal Cell Carcinoma2022

    • Author(s)
      Saiga K*, Ohe C* (*equally contributed), Yoshida T, Ohsugi H, Ikeda J, Atsumi N, Noda Y, Yasukochi Y, Higasa K, Taniguchi H, Kinoshita H, Tsuta K.
    • Journal Title

      Cancers (Basel)

      Volume: 14 Issue: 4 Pages: 1062-1062

    • DOI

      10.3390/cancers14041062

    • Related Report
      2022 Research-status Report 2021 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Integration of NRP1, RGS5, and FOXM1 expression, and tumour necrosis, as a postoperative prognostic classifier based on molecular subtypes of clear cell renal cell carcinoma2021

    • Author(s)
      Takashi Yoshida , Chisato Ohe , Junichi Ikeda , Naho Atsumi , Ryoichi Saito , Hisanori Taniguchi , Haruyuki Ohsugi , Motohiko Sugi , Koji Tsuta , Tadashi Matsuda , Hidefumi Kinoshita
    • Journal Title

      J Pathol Clin Res

      Volume: 7 Issue: 6 Pages: 590-603

    • DOI

      10.1002/cjp2.232

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Predictors of postoperative recurrence in patients with non-metastatic pT3a renal cell carcinoma2021

    • Author(s)
      Ohsugi H, Ohe C, Yoshida T, Ikeda J, Sugi M, Kinoshita H, Matsuda T.
    • Journal Title

      Int J Urol

      Volume: 28 Issue: 10 Pages: 1060-1066

    • DOI

      10.1111/iju.14648

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Journal Article] Tumor volume and tumor crossing of the axial renal midline predict renal function after robotic partial nephrectomy2021

    • Author(s)
      Ohsugi Haruyuki、Akiyama Kyojiro、Taniguchi Hisanori、Yanishi Masaaki、Sugi Motohiko、Matsuda Tadashi、Kinoshita Hidefumi
    • Journal Title

      Scientific Reports

      Volume: 11 Issue: 1 Pages: 22526-22526

    • DOI

      10.1038/s41598-021-01539-1

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Development and validation of a vascularity-based architectural classification for clear cell renal cell carcinoma: correlation with conventional pathological prognostic factors, gene expression patterns, and clinical outcomes2021

    • Author(s)
      Ohe C, Yoshida T, Amin MB, Atsumi N, Ikeda J, Saiga K, Noda Y, Yasukochi Y, Ohashi R, Ohsugi H, Higasa K, Kinoshita H and Tsuta K
    • Journal Title

      Mod Pathol

      Volume: - Issue: 6 Pages: 816-824

    • DOI

      10.1038/s41379-021-00982-9

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] The SSPN Score, a Novel Scoring System Incorporating PBRM1 Expression, Predicts Postoperative Recurrence for Patients with Non-metastatic Clear Cell Renal Cell Carcinoma2020

    • Author(s)
      Ohsugi Haruyuki、Yoshida Takashi、Ohe Chisato、Ikeda Junichi、Sugi Motohiko、Kinoshita Hidefumi、Tsuta Koji、Matsuda Tadashi
    • Journal Title

      Annals of Surgical Oncology

      Volume: 28 Issue: 4 Pages: 2359-2366

    • DOI

      10.1245/s10434-020-09075-4

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Presentation] Accurate calculation of tumor volume and tumor crossing of the axial renal midline are preoperative predictors of reduced estimated glomerular filtration rate after robotic partial nephrectomy2021

    • Author(s)
      Haruyuki Ohsugi
    • Organizer
      米国泌尿器科学会
    • Related Report
      2021 Research-status Report
    • Int'l Joint Research
  • [Presentation] A Novel Scoring System Integrating PBRM1 Expression to Predict Recurrence in Patients with Non-Metastatic Clear Cell Renal Cell Carcinoma Undergoing Radical Surgery.2020

    • Author(s)
      Haruyuki Ohsugi
    • Organizer
      米国泌尿器科学会
    • Related Report
      2020 Research-status Report
    • Int'l Joint Research
  • [Presentation] A novel scoring system integrating PBRM1 expression to predict recurrence in patients with non-metastatic clear cell renal cell carcinoma undergoing radical surgery.2020

    • Author(s)
      Haruyuki Ohsugi
    • Organizer
      欧州泌尿器科学会
    • Related Report
      2020 Research-status Report
    • Int'l Joint Research
  • [Presentation] PBRM1発現を組み込んだ淡明細胞型腎細胞癌の術後再発を予測するスコアリングシステム2020

    • Author(s)
      大杉治之
    • Organizer
      日本癌治療学会
    • Related Report
      2020 Research-status Report

URL: 

Published: 2020-04-28   Modified: 2024-12-25  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi